Introduction {#sec1-1}
============

Cervical cancer is the third most common cancer in women after breast and colorectal cancers and is one of the leading causes of cancer death among women in the world \[[@ref1]\]. In 2008, approximately 530,000 women were diagnosed with invasive cervical cancer worldwide and 275,000 women died from it \[[@ref1], [@ref2]\]. Cervical cancer is the top cancer site for women in most East African and South Asian countries both in terms of incidence and mortality\[[@ref1], [@ref2]\]. Indeed, developing countries as a whole experience a disproportionate share of the disease burden, accounting for 86% of all cervical cancer cases and 88% of all cervical cancer deaths worldwide \[[@ref1]-[@ref3]\] While cervical cancer rates have declined markedly in industrialized countries over the past several decades, the rates have declined at a much slower pace in the developing world and, for many developing countries, the rates have actually been increasing \[[@ref1], [@ref2]\]. The latest data from the World Health Organization (WHO) show marked disparities in cervical cancer incidence and mortality rates across countries \[[@ref1], [@ref2]\].

A number of population-based studies from the United States and other industrialized countries have shown marked socioeconomic gradients in cervical cancer incidence and mortality, with those in more deprived groups or lower socioeconomic strata having 2-3 fold higher risk of cervical cancer than their affluent counterparts \[[@ref4]-[@ref9]\]. A few case-control studies in Asia, Africa, and South America also indicate substantially higher risks of cervical cancer among women in lower social class groups \[[@ref9]\]. To our knowledge, the extent to which disparities in cervical cancer incidence and mortality rates between nations arise due to global differences in social inequality and human development factors has not yet been studied. Given the evidence of a strong association between socioeconomic status (SES) and cervical cancer from within-country studies, we should expect differences in education, socioeconomic conditions, material living standards, and health services to account for a substantial portion of global inequalities in cervical cancer incidence and mortality.

Assessing the impact of socioeconomic conditions and human development is important because they represent underlying causes of health inequalities both within and between nations \[[@ref10], [@ref11]\]. Improvements in the broader social determinants such as education, income distribution, gender inequality, labor force participation, employment, and health care have been suggested as central to reducing population health inequalities \[[@ref10], [@ref12]\]. International comparisons can highlight the extent of disease burden in specific countries and important cross-national differences and similarities in socioeconomic conditions, urbanization patterns, prevalence of cancer risk factors such as smoking and human papillomavirus (HPV) infection, and availability and use of cervical cancer screening programs \[[@ref2], [@ref4]\]. Analysis of global inequalities is also important in that cervical cancer tends to affect younger women (aged \<45 years) more than the other major cancers, resulting in relatively high years-of-life lost, particularly among women in the developing world \[[@ref2]\]. Moreover, cervical cancer rates appear to be rising among younger women in many developing as well as developed countries \[[@ref13]\].

The major purpose of our paper is to quantify the links between inequalities in human development and socioeconomic conditions and global disparities in cervical cancer incidence and mortality. Specifically, we link socioeconomic, demographic, and human development indicators for various countries with the most recent international cervical cancer data to examine global patterns of cervical cancer incidence and mortality. In addition, we document the extent of global disparities in cervical cancer by identifying regions and countries in which women are at high risk of morbidity and mortality from this disease.

Methods {#sec1-2}
=======

To analyze global inequalities in cervical cancer incidence and mortality, we computed age-adjusted incidence and mortality rates for women in 184 countries using the 2008 GLOBOCAN database \[[@ref1]\]. The GLOBOCAN database, developed by the International Agency for Research on Cancer, provides contemporary estimates of the incidence of, mortality and prevalence from major type of cancers, at national level, for 184 countries of the world \[[@ref1]\]. Details of the cancer database are provided elsewhere \[[@ref1], [@ref2]\]. Annual trends in incidence and mortality rates were analyzed for selected countries using the WHO cancer incidence and mortality databases \[[@ref14], [@ref15]\].

The data on the Human Development Index (HDI) and Gender Inequality Index (GII) were taken from the 2011 Human Development Report \[[@ref16]\], while those on Gross National Income (GNI) per capita, international poverty rate (deprivation level measuring the proportion of population living in extreme poverty), literacy rate, urbanization, and health expenditure came from the 2011 World Health Statistics Report \[[@ref17]\]. HDI, developed by the United Nations Development Programme, is a composite index of social and economic development and combines indicators of life expectancy, educational attainment, and GNI per capita. HDI varies between 0 and 1, with 0 indicating the lowest level and 1 representing the highest level of development \[[@ref16]\]. GII is also a composite index that reflects women's relative social disadvantage in three dimensions -- reproductive health, empowerment, and the labor market \[[@ref16]\]. GII combines 5 indicators, maternal mortality ratios, adolescent fertility rate, educational attainment, parliamentary representation by each sex, and female labor force participation \[[@ref16]\].

We used bivariate and multivariate ordinary least squares (OLS) regression models to estimate the impact of HDI, GII, and other socioeconomic factors on age-adjusted cervical cancer incidence and mortality rates. We used Poisson regression to model age- and country-specific incidence cases, deaths, and population estimates as a function of socioeconomic and human development factors \[[@ref11], [@ref18]\]. For Poisson modeling, we used three broad age-groups: \<45, 45-64, and 65+ years. The OLS models were estimated by the SAS REG procedure \[[@ref19]\], while Poisson models were estimated by the SAS GENMOD procedure \[[@ref20]\].

Since HDI and GII both include education and economic components, these composite indices are highly correlated with the other individual predictors used in the study, such as literacy rate, per capita income, poverty, and urbanization. Because of estimation problems due to high multicollinearity, multiple regression models containing either HDI or GII and education and income indicators were not estimated. Instead, the net impact of health expenditure per capita was examined in multivariate models that included HDI or GII.

Log-linear regression models were used to estimate annual rates of change in cervical cancer incidence and mortality trends for selected countries \[[@ref7], [@ref12], [@ref18]\]. Specifically, during the 1983-2002 or 1983-2008 period, the logarithm of the incidence or mortality rates respectively were modeled as a linear function of time (calendar year), which yielded annual exponential rates of change in incidence or mortality rates \[[@ref7], [@ref12], [@ref18]\].

Results {#sec1-3}
=======

Global Inequalities in Cervical Cancer Incidence and Mortality Rates {#sec2-1}
--------------------------------------------------------------------

In 2008, cervical cancer incidence and mortality rates were higher in Eastern, Western, and Sub-Saharan regions of Africa and South Asia and lower in Western Asia, Western Europe, North America, and Australia/New Zealand ([Figure 1](#F1){ref-type="fig"}). Overall, women in developing countries had two-fold higher cervical cancer incidence rates and three-fold higher mortality rates than their counterparts from developed countries.
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**Source:** WHO, International Agency for Research on Cancer, GLOBOCAN, 2008.](IJMA-1-17-g001){#F1}

Long-term trends in cervical cancer incidence and mortality vary across countries (Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). While incidence rates have generally decreased for most countries, the rates have remained stable at fairly high levels for certain countries such as Thailand (data not shown). During 1983-2002, although incidence rates decreased at 4.3%, 3.1%, and 1.7% per year in Brazil, India (Chennai), and the Philippines, respectively, they remained at much higher levels than those for Hong Kong and Shanghai, China ([Figure 2](#F2){ref-type="fig"}). Mortality trends have also not been uniform across countries. During 1983-2008, while mortality rates in Hong Kong and Singapore decreased at about 4% per year, the rates have either decreased at a much slower pace for Brazil and Mexico or increased for some countries such as Cuba, Venezuela ([Figure 3](#F3){ref-type="fig"}), Thailand, and the Philippines (trend not shown).

![Trend in Cervical Cancer Incidence Rates in Selected Countries, 1983-2002\
**Source:** WHO, International Agency for Research on Cancer, Cancer Incidence in Five Continents Annual Dataset.](IJMA-1-17-g002){#F2}

![Trend in Cervical Cancer Mortality Rates in Selected Countries, 1983-2008\
**Source:** WHO, International Agency for Research on Cancer, Cancer Mortality Database.](IJMA-1-17-g003){#F3}

In 2008, cervical cancer rates varied widely across individual countries, with many African countries such as Guinea, Zambia, Comoros, Tanzania, and Malawi having at least 10-to-20 fold higher incidence and mortality rates than such countries as Iran, Saudi Arabia, Syria, Egypt, and Switzerland ([Table 1](#T1){ref-type="table"}). Cross-national disparities in cervical cancer mortality rates (as measured by the coefficient of variation and range) were greater than those in incidence rates. Guinea had the highest age-adjusted incidence rate of 56.3 per 100,000 women, 35 times greater than the rate of 1.6 for Egypt. Guinea also had the highest age-adjusted mortality rate of 41.7 per 100,000 women, 52 times higher than the rate of 0.8 for Syria ([Table 1](#T1){ref-type="table"}).

###### 

Age-adjusted Cervical Cancer Incidence and Mortality Rates per 100,000 World Standard Population, 2008

                                                            Incidence cases                                           Age-adjusted incidence rate                            Deaths   Age-adjusted mortality Rate
  --------------------------------------------------------- --------------------------------------------------------- ----------------------------- ------------------------ -------- -----------------------------
  **Top 25 countries with the highest incidence rates**     **Top 25 countries with the highest mortality rates**                                                                     
  Guinea                                                    1,736                                                     56.3                          Guinea                   1,217    41.7
  Zambia                                                    1,839                                                     52.8                          Comoros                  76       39.1
  Comoros                                                   110                                                       51.7                          Zambia                   1,276    38.6
  Tanzania                                                  6,241                                                     50.9                          Malawi                   1,621    38.3
  Malawi                                                    2,316                                                     50.8                          Tanzania                 4,355    37.5
  Mozambique                                                3,690                                                     50.6                          Burundi                  900      37.2
  Swaziland                                                 198                                                       50.0                          Uganda                   2,464    34.9
  Burundi                                                   1,270                                                     49.1                          Mozambique               2,356    34.5
  Uganda                                                    3,577                                                     47.5                          Zimbabwe                 1,286    33.4
  Zimbabwe                                                  1,855                                                     47.4                          Sierra Leone             466      33.0
  Jamaica                                                   624                                                       45.7                          Swaziland                116      31.4
  Guyana                                                    161                                                       44.7                          Liberia                  341      31.2
  Sierra Leone                                              670                                                       41.9                          Mali                     1,010    28.4
  Liberia                                                   487                                                       41.8                          Ghana                    2,006    27.6
  Nicaragua                                                 869                                                       39.9                          Guinea-Bissau            130      26.0
  Ghana                                                     3,038                                                     39.5                          Mauritania               244      25.5
  Honduras                                                  1,014                                                     37.8                          Senegal                  795      25.5
  Mali                                                      1,491                                                     37.7                          Rwanda                   678      25.4
  El Salvador                                               1,145                                                     37.2                          Gambia                   133      24.4
  Bolivia                                                   1,422                                                     36.4                          Benin                    616      24.4
  Mauritania                                                364                                                       35.1                          Nigeria                  9,659    22.9
  Guinea-Bissau                                             185                                                       35.1                          Lesotho                  178      22.7
  Benin                                                     925                                                       35.0                          Angola                   1,008    21.9
  Lesotho                                                   279                                                       35.0                          Togo                     417      21.8
  Paraguay                                                  864                                                       35.0                          Burkina Faso             838      21.5
  **Bottom 15 countries with the lowest incidence rates**   **Bottom 15 countries with the lowest mortality rates**                                                                   
  Cyprus                                                    27                                                        4.5                           Greece                   172      1.6
  Finland                                                   151                                                       4.5                           Turkey                   556      1.6
  Turkey                                                    1,443                                                     4.2                           New Zealand              53       1.6
  Greece                                                    345                                                       4.1                           Italy                    906      1.5
  Switzerland                                               221                                                       4.0                           Australia                241      1.4
  Lebanon                                                   85                                                        3.8                           Finland                  63       1.2
  Jordan                                                    71                                                        3.6                           Iran                     286      1.0
  Iraq                                                      309                                                       3.1                           Egypt                    299      1.0
  Yemen                                                     162                                                       3.0                           Switzerland              72       0.9
  Iran                                                      643                                                       2.2                           Saudi Arabia             55       0.8
  Saudi Arabia                                              152                                                       2.1                           Syria                    54       0.8
  Malta                                                     7                                                         2.1                           Iceland                  4        0.8
  Syria                                                     140                                                       2.0                           Gaza Strip & West Bank   3        0.3
  Egypt                                                     514                                                       1.6                           Qatar                    1        0.3
  Gaza Strip & West Bank                                    5                                                         0.4                           United Arab Emirates     2        0.2

**Source:** WHO, International Agency for Research on Cancer (IARC), GLOBOCAN 2008.

Modeling the Impact of HDI, GII, and Socioeconomic Factors {#sec2-2}
----------------------------------------------------------

HDI, GII, international poverty rate, health expenditure per capita, urbanization, and literacy rate were all significantly related to Cancer incidence and mortality, with HDI and poverty rate each explaining \>52% of the global variance in mortality ([Table 2](#T2){ref-type="table"} and [Figure 4](#F4){ref-type="fig"}). Both incidence and mortality rates increased in relation to lower levels of human development and higher levels of gender inequality. In bivariate models, a 0.2 unit increase in HDI was on average associated with an 8.7 point decrease in incidence rates and a 7.8 point decrease in mortality rates. A 0.2 unit increase in HDI was associated with a 20% decrease in the risk of cervical cancer incidence and a 33% decrease in the risk of cervical cancer mortality ([Table 2](#T2){ref-type="table"}).

###### 

Ordinary Least Squares (OLS) and Poisson Regression Models Showing the Effects of Human Development Index, Gender Inequality Index, and Socioeconomic and Health Care Factors on Age-Adjusted Cervical Cancer Incidence and Mortality Rates, 2008 (N = 184 Countries)

  Covariate                                                                      OLS Models   Poisson Models                                                 
  ------------------------------------------------------------------------------ ------------ ---------------- -------- --------- ------- ------ ----------- ---------
  **Cervical cancer incidence**                                                                                                                              
                                                                                                                                                             
  **Bivariate models**                                                                                                                                       
                                                                                                                                                             
  Human Development Index (HDI)^[a](#t2f1){ref-type="table-fn"}^                 -8.72        -0.60            -9.60    \<0.001   35.86   0.80   0.80−0.80   \<0.001
                                                                                                                                                             
  Gender Inequality Index^[b](#t2f2){ref-type="table-fn"}^                       7.06         0.50             6.66     \<0.001   24.28   1.24   1.24−1.25   \<0.001
                                                                                                                                                             
  Adult literacy rate^[c](#t2f3){ref-type="table-fn"}^                           -5.15        -0.36            -4.53    \<0.001   12.53   0.89   0.89−0.89   \<0.001
                                                                                                                                                             
  Gross National Income per capita (Int. \$)^[d](#t2f4){ref-type="table-fn"}^    -2.29        -0.51            -7.73    \<0.001   25.55   0.92   0.92−0.92   \<0.001
                                                                                                                                                             
  Poverty rate (PPP international \$)^[e](#t2f5){ref-type="table-fn"}^           2.94         0.57             6.90     \<0.001   31.33   1.08   1.08−1.08   \<0.001
                                                                                                                                                             
  Urban population (%)^[f](#t2f6){ref-type="table-fn"}^                          -2.60        -0.45            -6.64    \<0.001   19.83   0.94   0.94−0.94   \<0.001
                                                                                                                                                             
  Health expenditure per capita (PPP int. \$)^[g](#t2f7){ref-type="table-fn"}^   -4.62        -0.46            -6.81    \<0.001   20.88   0.88   0.88−0.89   \<0.001
                                                                                                                                                             
  **Multivariate models**                                                                                                                                    
                                                                                                                                                             
  Model 1: Human Development Index+                                              -7.25        -0.50            -5.41    \<0.001   34.67   0.89   0.89−0.90   \<0.001
                                                                                                                                                             
   Health expenditure per capita                                                 -1.28        -0.13            -1.40    0.162             0.92   0.92−0.93   \<0.001
                                                                                                                                                             
  Model 2: Gender Inequality Index+                                              3.95         0.28             2.67     \<0.009   27.36   1.18   1.17−1.18   \<0.001
                                                                                                                                                             
   Health expenditure per capita                                                 -2.74        -0.29            -2.76    \<0.007           0.93   0.93−0.93   \<0.001
                                                                                                                                                             
  **Cervical cancer mortality**                                                                                                                              
                                                                                                                                                             
  **Bivariate models**                                                                                                                                       
                                                                                                                                                             
  Human Development Index (HDI)^[a](#t2f1){ref-type="table-fn"}^                 -7.80        -0.72            -13.36   \<0.001   52.12   0.67   0.67−0.67   \<0.001
                                                                                                                                                             
  Gender Inequality Index^[b](#t2f2){ref-type="table-fn"}^                       5.93         0.58             8.21     \<0.001   32.97   1.42   1.41−1.43   \<0.001
                                                                                                                                                             
  Adult literacy rate^[c](#t2f3){ref-type="table-fn"}^                           -4.60        -0.46            -6.06    \<0.001   20.69   0.79   0.78−0.79   \<0.001
                                                                                                                                                             
  Gross National Income per capita (Int. \$)^[d](#t2f4){ref-type="table-fn"}^    -1.79        -0.54            -8.31    \<0.001   28.47   0.86   0.86−0.86   \<0.001
                                                                                                                                                             
  Poverty rate (PPP international \$)^[e](#t2f5){ref-type="table-fn"}^           2.91         0.73             10.65    \<0.001   52.45   1.14   1.14−1.14   \<0.001
                                                                                                                                                             
  Urban population (%)^[f](#t2f6){ref-type="table-fn"}^                          -2.25        -0.53            -8.22    \<0.001   27.56   0.89   0.88−0.89   0.327
                                                                                                                                                             
  Health expenditure per capita (PPP int. \$)^[g](#t2f7){ref-type="table-fn"}^   -3.58        -0.49            -7.28    \<0.001   23.11   0.81   0.80−0.81   \<0.001
                                                                                                                                                             
  **Multivariate models**                                                                                                                                    
                                                                                                                                                             
  Model 1: Human Development Index+                                              -7.80        -0.72            -9.02    \<0.001   50.37   0.73   0.73−0.74   \<0.001
                                                                                                                                                             
   Health expenditure per capita                                                 0.08         0.01             0.13     0.897             0.92   0.92−0.92   \<0.001
                                                                                                                                                             
  Model 2: Gender Inequality Index+                                              4.23         0.42             4.17     \<0.001   34.38   1.31   1.30−1.32   \<0.001
                                                                                                                                                             
   Health expenditure per capita                                                 -1.46        -0.22            -2.15    0.033             0.89   0.89−0.90   \<0.001

Notes: b=unstandardized regression coefficient; β=standardized regression coefficient; R^2^ =percentage variance explained.

β is also equal to the correlation coefficient in bivariate OLS regression models

Increase in incidence/mortality rates or risks associated with a 0.2 unit increase in HDI

Increase in incidence/mortality rates or risks associated with a 0.2 unit increase in the Gender Inequality Index

Increase in incidence/mortality rates or risks associated with a 20-percentage point increase in the adult literacy rate

Increase in incidence/mortality rates or risks associated with a \$5,000 increase in GNI per capita

Increase in incidence/mortality rates or risks associated with a 10-percentage point increase in the poverty rate

Increase in incidence/mortality rates or risks associated with a 10-percentage point increase in the urban population

Increase in incidence/mortality rates or risks associated with a \$1,000 increase in health expenditure per capita

![Observed and Fitted Plots Showing the Impact of Human Development Index (HDI) and Poverty on Age-Adjusted Cervical Cancer Mortality Rates per 100,000 World Standard Population, 2008](IJMA-1-17-g004){#F4}

Cervical cancer incidence and mortality rates increased by 7.1 and 5.9 points, respectively, for every 0.2 unit increase in GII. The risk of a cervical cancer diagnosis increased by 24% and of cervical cancer death by 42% for a 0.2 unit increase in GII ([Table 2](#T2){ref-type="table"}). GII explained approximately 24% and 33% of the global variance in incidence and mortality rates, respectively.

Deprivation levels or poverty rates were a strong predictor of cross-national variations in cervical cancer incidence and mortality. A 10-percentage point increase in poverty rates was expected to result in an 8% higher risk of incidence and a 14% higher risk of death from cervical cancer. A \$5,000 increase in GNI per capita was associated with an 8% lower incidence risk and a 14% lower mortality risk. Incidence risks decreased by 11% and mortality risks by 21% for every 20-percentage point increase in literacy rate. Incidence and mortality rates and risks decreased at increasing levels of urbanization ([Table 2](#T2){ref-type="table"}).

In multivariate models, higher health expenditure levels were independently associated with decreased incidence and mortality risks. Even after adjusting for the effects of HDI or GII, for every \$1,000 increase in healthcare expenditure per capita, there was at least a 7% decrease in the risk of cervical cancer ([Table 2](#T2){ref-type="table"}). The corresponding net decrease in cervical cancer mortality risk was 8-11% for a similar increase in health expenditure per capita.

Discussion {#sec1-4}
==========

In this study, by using the latest global sociodemographic, health, and cancer statistics, we have identified countries at high risk of cervical cancer morbidity and mortality and have examined the impact of socioeconomic and human development factors on cross-national variations in cervical cancer incidence and mortality rates. High rates of incidence and mortality observed for many low- and middle-income countries indicate cervical cancer to be a major public health problem in the developing world \[[@ref2]\]. In terms of absolute numbers, Indian women bear the greatest burden of the disease as more than a quarter of new cases and cervical cancer deaths in the world occur in India alone \[[@ref1], [@ref2]\].

We have estimated the magnitude of cervical cancer disparities between countries and attempted to explain these disparities in terms of the effects of major societal determinants. It is important to note that social inequalities in cervical cancer are quite marked within individual countries as well \[[@ref4], [@ref6],[@ref8], [@ref9]\]. As mentioned earlier, this pattern holds for both developed and developing countries \[[@ref4], [@ref8], [@ref9]\]. However, population-based studies of social inequalities are rare for the developing countries that have the greatest disease burden; more studies are needed in these countries to shed light on the magnitude and causes of social inequalities in cervical cancer incidence and mortality.

The findings of our study are consistent with two earlier studies that examined global patterns in cervical cancer rates using the 2008 GLOBOCAN database \[[@ref2], [@ref3]\]. These studies examined disparities in incidence and mortality rates across countries and various regions of the world in much detail \[[@ref2], [@ref3]\]. However, unlike our study, no efforts were made in these studies to link cervical cancer disparities with global patterns of human development and socioeconomic conditions.

Global inequalities in cervical cancer mortality are substantially larger than those in cervical cancer incidence, which indicate the prominent role of cross-national disparities in patient survival rates, the extent of disease at diagnosis, and the impact of differential access to health services and cancer treatment \[[@ref4]-[@ref8]\]. Cancer survival varies greatly across countries, with cancer patients in Europe, North America, Australia and New Zealand having higher survival rates than their counterparts in developing countries \[[@ref21]\]. A recent study showed wide variation in cervical cancer survival rates among African, Asian, Caribbean, and Central American countries \[[@ref22]\]. The 5-year age-standardized relative survival rate for cervical cancer ranged from a low of 19% in Uganda and 23% in Gambia to a high of 76% in Seoul, South Korea and 77% in Hong Kong, China \[[@ref22]\]. The current 5-year relative survival rate is 69% for US women \[[@ref23]\]. Survival inequalities exist within individual countries as well. For example, the 5-year survival rate for cervical cancer patients in Bhopal, India was 31%, as compared with 60% for women in Chennai, India \[[@ref22]\].

Lower cancer survival and higher mortality rates partly result from higher rates of late-stage cancer diagnosis among women in developing countries, which is largely due to the lack of effective cervical cancer screening programs in most developing countries \[[@ref2], [@ref4], [@ref24]\]. About 81% of cervical cancer patients in Singapore are diagnosed at an early, localized stage, compared with only 7% in Chennai, India, 33% in Costa Rica, 35% in Manila, Philippines, and 53% in Cuba \[[@ref24]\]. The high rate of early-stage diagnosis in Singapore is higher than the rate for many industrialized countries, including the United States, where only 52% of invasive cervical cancers in 2008 were diagnosed at localized stage \[[@ref7], [@ref23]\].

Detection of cancer at an early stage may be considered a marker for access to health care and preventive health services, including cervical cancer screening. Screening can reduce rates of both cervical cancer incidence and mortality by detecting precancerous lesions (hence preventing cancer) and detecting invasive cervical cancers at an early stage, thereby increasing patient survival \[[@ref4], [@ref7], [@ref25]\]. Data from the United States and other industrialized countries indicate that rural and socioeconomically disadvantaged women are significantly less likely to receive Pap smear tests than their urban and affluent counterparts \[[@ref4], [@ref5], [@ref7], [@ref8]\]. According to a recent study, only 19% of women in developing countries use cervical cancer screening, compared with 63% in developed countries \[[@ref24]\]. However, rates of cervical cancer screening vary widely within the developing world, ranging from 1% in Bangladesh to 73% in Brazil \[[@ref24]\]. Consistent with inequalities in cervical cancer screening within the developed world, socioeconomic inequalities in countries such as Brazil and China are quite large, and, globally, women in the poorest wealth decile are seven times less likely to receive cervical cancer screening than their rich counterparts (9% versus 64%) \[[@ref24]\].

Inequalities in cervical cancer partly reflect global disparities in the prevalence of HPV infection, which is the primary cause of cervical cancer \[[@ref2], [@ref4], [@ref9], [@ref13], [@ref26]\]. HPV prevalence tends to be higher in Eastern and Western Africa, Latin America, and South Asia and lower in West Asia and the Mediterranean region \[[@ref2], [@ref27]\]. Globally, HPV prevalence seems to correspond closely with cervical cancer incidence rates (γ= 0.68) \[[@ref2]\]. Another indicator of high-risk sexual behavior is the HIV prevalence among the adult population, which, according to our analysis (not shown), is fairly highly correlated (γ\> 0.40) with both cervical cancer incidence and mortality rates globally.

Conclusions and Public Health Implications {#sec1-5}
==========================================

Developing and developed countries differ greatly in their levels of human development and gender inequality \[[@ref16]\]. Many of the countries with the highest cervical cancer rates such as Guinea, Comoros, Zambia, Malawi, Burundi, and Mozambique also tend to score the lowest on HDI. Countries with low levels of human development also tend to perform poorly with respect to gender equality; women in these societies fare much worse in reproductive health, educational achievements, empowerment, and work force participation than their counterparts in more egalitarian countries \[[@ref16]\]. As shown previously for the United States and other individual industrialized countries, deprivation, material living conditions, and social inequality are also powerful determinants of cervical cancer incidence and mortality at the global level.

The extent of global inequalities in cervical cancer incidence and mortality, as documented here, contributes substantially to the overall cancer-related health disparities worldwide, since cervical cancer continues to be a leading cancer site among women in many developing countries \[[@ref1], [@ref2]\]. Unfavorable socioeconomic conditions and low levels of human development may hinder a country's efforts to invest in its health care infrastructure, provision of health services, and in its education sector, which could mean less than optimal resources available for public health improvement and cancer prevention and control efforts. Formulation and implementation of broad societal initiatives are, of course, necessary to address important health and developmental goals, including poverty reduction, larger investments in women's health and education, expanding economic opportunities for women, and a greater commitment toward gender and social equality in the distribution of power, money, and resources \[[@ref11], [@ref16], [@ref17]\]. Additionally, public health measures such as establishment of cancer prevention and early detection programs through increased cervical cancer screening, public health education programs promoting condom use to reduce risks of sexually transmitted infections such as HPV and HIV, and introduction of affordable HPV tests and vaccination are critical in reducing global cervical cancer disparities, particularly among women in low- and middle-income developing countries \[[@ref2]\].
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